These findings show that GLP-1 agonists can be game changers in improving blood glucose control and body weight and in reducing risk of cardiovascular events and death
Dunn L, Allen GF, Mamais A, Ling H, Li A, Duberley KE, et al
Emerging options worth knowing about The GLP-1 landscape is expanding rapidly
For a broader view of related compounds, the GLP-3 peptide and amylin receptor agonist guides cover emerging targets in the metabolic peptide space that may eventually offer weight loss with fewer side effects
124 GLP-1, by activating its receptor, increases insulin secretion and reduces glucagon secretion, thereby lowering blood sugar levels
It is not prescribing guidance, a recommendation, or encouragement to use, obtain, or supply any medicine